AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation. We develop our product candidates to address emerging biological targets using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, or SHM, and replicates this natural process of antibody generation in vitro. Our strategy is to advance the development and commercialization of our proprietary product candidates, and for certain programs, establish partnerships with leading biopharmaceutical companies where we retain certain development and commercialization rights in the United States.
Our wholly-owned product pipeline includes ANB020 and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. We are advancing our ANB020 product candidate, an antibody that inhibits the activity of interleukin-33, for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy and severe adult eosinophilic asthma.
In addition, we are developing our ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP).
Our company is led by a strong management team with a proven track record of successfully growing biotechnology companies with deep experience in antibody discovery and development, collaborations, operations and corporate finance.
Additionally, multiple AnaptysBio-generated antibodies have entered the clinic under our immuno-oncology-focused collaboration with TESARO and inflammation-focused collaboration with Celgene.
Advancing our lead wholly-owned programs for the treatment of severe inflammatory disease
We plan to develop our proprietary anti-IL-33 antibody (ANB020) for the treatment of severe adult asthma and severe adult peanut allergy. In addition, we intend to develop our anti-IL-36R antibody (ANB019) for the treatment of generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP).
Identifying emerging target biology opportunities in inflammation
We intend to remain at the forefront of discovery and development of new therapeutic opportunities in inflammation by understanding and translating biological breakthroughs into first-in-class therapeutic antibodies. Our approach includes assessment of human genetics and tissue pathology to understand the relevance of emerging targets to patients with unmet medical needs. We plan to leverage this knowledge to create new product candidates and position our current and future programs for rapid clinical proof-of-concept achievement.
Expanding our proprietary pipeline by generating new antibody product candidates using our technology platform
Using our proprietary antibody generation platform, we are able to rapidly develop novel therapeutic antibodies against emerging targets. Our goal is to advance multiple additional wholly-owned new therapeutic antibody program to IND submission.
Retaining rights to strategic products in key commercial markets
We intend to retain ownership and control of our pipeline programs to key inflection points. We may build sales and marketing capabilities in selected specialty markets that we believe can be served with a focused commercial organization. For certain programs, we plan to seek strategic collaborations that provide us with funding, infrastructure and marketing resources to advance through development and commercialization.
Board Of Directors
Jamie Topper, M.D., Ph.D., is a Managing General Partner of Frazier Healthcare Partner’s Life Sciences team.+
Hollings Renton has previously served as the Chief Executive Officer and President of Onyx Pharmaceuticals from 1993 to 2008 and as the Chairman of the Board from 2000 to 2008.+
John Schmid served as Chief Financial Officer of Auspex Pharmaceuticals, Inc. from September 2013 until its sale to Teva Pharmaceuticals, Inc. in June 2015. Prior to Auspex, he co-founded Trius Therapeutics, Inc., where he served as Chief Financial Officer from June 2004 until its merger with Cubist Pharmaceuticals, Inc.+
Dr. Fenton held positions of increasing responsibility at Amgen from 1982 through to his retirement in 2008, including Vice President of Research, Senior Vice President of Sales and Marketing, Senior Vice President of Operations and Executive Vice President.+
Nick Lydon, Ph.D., FRS, has extensive experience in drug discovery and development and is a recipient of the Lasker Prize and other awards for his achievements in medicine.+
Dr. Ware currently serves as the Senior Vice President of Product Development of Lilly Bio-Medicines at Eli Lilly and Company, where he is responsible for the clinical development and regulatory approval of new medicines in multiple therapeutic areas.+
Therapeutic Advisory Board
David L. Lacey, M.D., is a former Senior Vice President and Head of Discovery Research at Amgen with over 30 years of basic and clinical research experience.+
Michael Gallatin, Ph.D., is a former Vice President and Scientific Director of ICOS Corporation, where his responsibilities included discovery, preclinical research, medicinal chemistry and process chemistry groups, including those responsible for worldwide development and launch of Tadalafil (Cialis®).+
Jan de Vries, Ph.D., is the former Head of the Novartis Research Institutes for BioMedical Research in Basel, Switzerland. Prior to that, he was Head of the Novartis Research Institute in Vienna and Global Head of the Disease Area Autoimmunity, Transplantation and Inflammation.+